X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (232) 232
hematology (152) 152
female (136) 136
male (131) 131
middle aged (130) 130
index medicus (117) 117
adult (110) 110
aged (89) 89
prognosis (69) 69
mutation (66) 66
oncology (66) 66
leukemia, myeloid, acute - genetics (65) 65
adolescent (55) 55
life sciences (41) 41
cancer (40) 40
acute myeloid-leukemia (37) 37
leukemia (37) 37
acute myeloid leukemia (36) 36
abridged index medicus (35) 35
treatment outcome (35) 35
myelodysplastic syndromes - genetics (33) 33
young adult (32) 32
leukemia, myeloid, acute - drug therapy (31) 31
hemic and lymphatic diseases (30) 30
mutations (29) 29
aged, 80 and over (28) 28
aml (28) 28
myelodysplastic syndromes (27) 27
chemistry (25) 25
child (25) 25
survival analysis (25) 25
beer (24) 24
biochemistry (24) 24
compositions or test papers therefor (24) 24
condition-responsive control in microbiological orenzymological processes (24) 24
disease-free survival (24) 24
enzymology (24) 24
measuring or testing processes involving enzymes, nucleicacids or microorganisms (24) 24
metallurgy (24) 24
microbiology (24) 24
mutation or genetic engineering (24) 24
processes of preparing such compositions (24) 24
spirits (24) 24
vinegar (24) 24
wine (24) 24
antineoplastic combined chemotherapy protocols - therapeutic use (22) 22
compositions thereof (22) 22
culture media (22) 22
expression (22) 22
karyotyping (22) 22
microorganisms or enzymes (22) 22
minimal residual disease (22) 22
nucleotides (22) 22
propagating, preserving or maintaining microorganisms (22) 22
acute myelogenous leukemia (21) 21
chemotherapy (21) 21
child, preschool (21) 21
derivatives thereof (21) 21
immunology (21) 21
nucleic acids (21) 21
nucleosides (21) 21
organic chemistry (21) 21
sugars (21) 21
leukemia, myeloid, acute - pathology (20) 20
cytogenetics (19) 19
genetic aspects (19) 19
leukemia, myeloid, acute - mortality (19) 19
leukemia, myeloid, acute - diagnosis (18) 18
research (18) 18
translocation, genetic (18) 18
diagnosis (17) 17
nuclear proteins - genetics (17) 17
remission induction (17) 17
survival rate (17) 17
analysis (16) 16
france (16) 16
infant (16) 16
retrospective studies (16) 16
survival (16) 16
acute disease (15) 15
dna mutational analysis (15) 15
gene (15) 15
imatinib mesylate (15) 15
leukemia, myelogenous, chronic, bcr-abl positive - genetics (15) 15
leukemia, myeloid - genetics (15) 15
myelodysplastic syndromes - pathology (15) 15
antineoplastic agents - therapeutic use (14) 14
in situ hybridization, fluorescence (14) 14
molecular sequence data (14) 14
myelodysplastic syndromes - drug therapy (14) 14
prospective studies (14) 14
recurrence (14) 14
risk factors (14) 14
abnormalities (13) 13
acute lymphoblastic-leukemia (13) 13
bone marrow - pathology (13) 13
cohort studies (13) 13
cytarabine - administration & dosage (13) 13
hematology, oncology and palliative medicine (13) 13
lymphoma (13) 13
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9825, pp. 1508 - 1516
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2010, Volume 28, Issue 5, pp. 808 - 814
Journal Article
Blood, ISSN 0006-4971, 03/2013, Volume 121, Issue 12, pp. 2213 - 2223
Journal Article
PLoS ONE, ISSN 1932-6203, 02/2016, Volume 11, Issue 2, p. e0148264
Journal Article
Journal Article
Journal Article
Nature, ISSN 0028-0836, 12/2016, Volume 540, Issue 7633, pp. 433 - 437
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 07/2013, Volume 31, Issue 19, pp. 2428 - 2436
Journal Article
Oncotarget, ISSN 1949-2553, 09/2018, Volume 9, Issue 74, pp. 33869 - 33870
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2010, Volume 363, Issue 26, pp. 2511 - 2521
In this study, adding pegylated interferon alfa-2a to imatinib therapy for chronic myeloid leukemia resulted in a greater reduction in the number of cells... 
CHRONIC MYELOGENOUS LEUKEMIA | CHROMOSOME | MEDICINE, GENERAL & INTERNAL | INTERFERON | CML | ABL TYROSINE KINASE | HEMATOPOIETIC STEM-CELLS | FOLLOW-UP | PATIENTS RECEIVING IMATINIB | QUIESCENT | CYTARABINE | Piperazines - administration & dosage | Humans | Leukemia, Myeloid, Chronic-Phase - pathology | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Polyethylene Glycols - adverse effects | Male | Proto-Oncogene Proteins c-abl - analysis | Cytarabine - adverse effects | Recombinant Proteins | RNA, Neoplasm - analysis | Adult | Female | Transcription, Genetic | Neutropenia - chemically induced | Proto-Oncogene Proteins c-abl - genetics | Pyrimidines - administration & dosage | Leukemia, Myeloid, Chronic-Phase - drug therapy | Anemia - chemically induced | Treatment Outcome | Thrombocytopenia - chemically induced | Imatinib Mesylate | Piperazines - adverse effects | Remission Induction | Cytarabine - administration & dosage | Polyethylene Glycols - administration & dosage | Interferon-alpha - administration & dosage | Leukemia, Myeloid, Chronic-Phase - mortality | Fusion Proteins, bcr-abl - genetics | Fusion Proteins, bcr-abl - analysis | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrimidines - adverse effects | Survival Analysis | Stem Cells - drug effects | Interferon-alpha - adverse effects | Benzamides | Drug therapy | Chronic myeloid leukemia | Medical research | Kinases | Leukemia | Manuscripts
Journal Article